Philippe Rousselot, MD, PhD from Versailles Hospital and University, Versailles, France, discusses the role of inotuzumab ozogamicin in acute lymphoblastic leukemia (ALL) patients in the relapsed/refractory setting. Inotuzumab ozogamicin is an investigational antibody-drug immunoconjugate, with an CD22 affinity. Inotuzumab ozogamicin works by targeting CD22, once internalized into the malignant cell, it is combined with calicheamicin (a sort of chemotherapy) which is then released to destroy it. Prof. Rousselot mentions how inotuzumab ozogamicin can also have some toxicities, mainly of the platelets and the liver. He talks about a study (NCT01564784) presented at the congress which compared inotuzumab ozogamicin with the best available therapy used at the moment. The results show a promising increase in complete remission (CR) and molecular response rate, however, not so much in terms of survival. Prof. Rousselot concludes the talk by emphasizing the continuous use of this drug in the best possible way, in order to improve the survival rate for patients. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.